The growth-hormone axis has two natural inputs: growth-hormone-releasing hormone, which stimulates release, and ghrelin, which amplifies it through a separate receptor. Ipamorelin and tesamorelin are research tools for those two inputs respectively, which is why comparing them as though they were competing versions of one thing produces confusion.
Everything below describes published laboratory and clinical literature. Both compounds are supplied for research use only.
The one-line version
- Ipamorelin: a selective agonist at the growth hormone secretagogue receptor, the ghrelin receptor. A pentapeptide.
- Tesamorelin: a stabilised analogue of growth-hormone-releasing hormone, acting at the GHRH receptor. A 44-amino-acid peptide with a trans-3-hexenoyl modification.
Side by side
| Property | Ipamorelin | Tesamorelin |
|---|---|---|
| Receptor | Growth hormone secretagogue receptor (ghrelin receptor) | GHRH receptor |
| Class | Growth hormone secretagogue, pentapeptide | GHRH analogue, 44 amino acids |
| Selectivity note | Studied specifically for minimal cortisol and prolactin cross-reactivity relative to earlier secretagogues | Acts on the native GHRH pathway, so signalling remains pulse-dependent |
| Published stage | Preclinical and early clinical literature | Completed clinical programme, an approved indication exists in some jurisdictions |
| Typical research context | Selectivity and pulsatility studies in the GH axis | Visceral adipose tissue and metabolic endpoints in the GH axis |
| Handling | Lyophilised, standard reconstitution | Lyophilised, standard reconstitution |
Ipamorelin: selectivity as the point
Ipamorelin is a pentapeptide agonist at the ghrelin receptor. Its place in the literature comes from selectivity rather than potency: earlier secretagogues in the same family were reported to move cortisol and prolactin alongside growth hormone, which makes any downstream observation hard to attribute. Ipamorelin was characterised specifically against that problem.
For research design that matters more than it sounds. A tool that moves one output is a cleaner instrument than a tool that moves three, regardless of which produces the larger effect.
Tesamorelin: the native pathway
Tesamorelin is a stabilised GHRH analogue. The trans-3-hexenoyl group on the N-terminus is what protects it from rapid degradation by DPP-4, which is the same class of problem semaglutide solves with its Aib substitution.
Because it acts on the native GHRH receptor, the pituitary response stays pulse-dependent and subject to the axis regulation that is already there. That is the mechanistic argument for it as a research tool: it works with the feedback loop rather than around it.
It also has the deeper clinical record of the two, with a completed programme around visceral adipose tissue endpoints.
Which one for which question
If the question is about the ghrelin receptor, about secretagogue selectivity, or about what happens when you amplify release without touching the GHRH arm, ipamorelin is the instrument.
If the question is about the GHRH pathway itself, or about metabolic endpoints where the published human literature gives you a reference point, tesamorelin is.
Studies that include both exist, and the logic is the same as the BPC-157 and TB-500 pairing: two different receptors are two different variables, which is informative in a design that intends it and confounding in one that does not.
A note on sourcing
Tesamorelin is a 44-amino-acid peptide with a specific N-terminal modification, which makes it genuinely difficult and expensive to synthesise correctly. That is precisely the profile of a compound that gets substituted in the grey market.
Mass spectrometry is the check that matters here: purity alone tells you the vial contains one thing consistently, not that the thing is what the label says. Both figures are on the certificate for the lot we ship.
For research use only. Everything above describes laboratory practice and published research. It is not medical advice, not dosing guidance, and carries no implication of human or veterinary use.